Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma

Melanoma Research

Volumn 13, Issue 1, 2003, Pages 59-66

  Oratz, Ruth ^a   Hauschild, Axel ^b   Sebastian, Günther ^c   Schadendorf, Dirk ^d   Castro, Dan ^e   Bröcker, Eva B ^f   Orenberg, Elaine K ^g  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g Matrix Pharmaceutical Inc   (United States)

Author keywords

Cisplatin; Intratumoral chemotherapy; Melanoma

Indexed keywords

ADRENALIN; CARMUSTINE; CISPLATIN; DACARBAZINE; INTERFERON; MELANOMA VACCINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHROPATHY; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EROSION; ERYTHEMA; FEMALE; FEVER; GAIT DISORDER; GEL; HUMAN; INFECTION; MALE; MELANOMA; MULTICENTER STUDY; NAUSEA; NECROSIS; OPEN STUDY; OTOTOXICITY; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SKIN METASTASIS; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; ULCER; VOMITING; WHEEZING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; EPINEPHRINE; FEMALE; GELS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MELANOMA; MIDDLE AGED; PILOT PROJECTS; SAFETY; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS;

EID: 0037332294     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200302000-00010     Document Type: Article

References (48)

1. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 6th edition. Philadelphia: Lippincott Williams & Wilkins; 2001, p. 2029.
2. Wagner JD, Gordon MS, Chuang T-Y, Coleman JJ III. Current therapy of cutaneous melanoma. Plast Reconstr Surg 2000; 105:1774-1799.
3. Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer 2000; 89:1983-1991.
4. Shapiro RL, Oratz R, Roses DF. Treatment of regionally recurrent malignant melanoma. Adv Oncol 1999; 15:15-21.
5. Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery 1994; 115:295-302.
6. Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995; 110:119-129.
7. Ricaniadis N, Konstadoulakis MM, Walsh D, Karakousis CP. Gastrointestinal metastases from malignant melanoma. Surg Oncol 1995; 4:105-110.
8. Ollila DW, Essner R, Wanek LA, Morton DL. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 1996; 131:975-980.
9. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20 year experience. Int J Radiat Oncol Biol Phys 1999; 44:607-618.
10. Geara FB, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am 1996; 76:1383-1398.
11. Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995; 2:445-449.
12. Rate WR, Solin LJ, Turrisi, AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol Biol Phys 1988; 15:859-864.
13. Ma D, Ariyan S. The use of isolated limb perfusion to manage recurrent malignant melanoma. Clin Plast Surg 2000; 27:441-450.
14. Hafström L, Rudenstam CM, Blomquist E, Ingvar C, Jönsson P-E, Lagerlöf B, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9:2091-2094.
15. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995; 1:122-130.
16. Vrouenraets BC, Eggermont AMM, Hart AA, Klaase JM, van Geel AN, Nieweg OE, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001; 27:390-395.
17. Lejeune FJ, Kroon BB, Di Filippo F, Hoekstra HJ, Santinami M, Lienard D, et al. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001; 10:821-832.
18. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology 1995; 9:1149-1558.
19. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997; 9:205-213.
20. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17:968-975.
21. Strobbe LJA, Nieweg OE, Kroon BBR. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol 1997; 23:435-438.
22. Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996; 83:509-512.
23. Lingam MK, McKay AJ. Carbon dioxide laser ablation as an alternative treatment for cutaneous metastases from malignant melanoma. Br J Surg 1995; 82:1346-1348.
24. Karrer S, Szeimies RM, Hohenleutner U, Landthaler M. Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. Am J Clin Dermatol 2001; 2:229-237.
25. Zeitouni NC, Shieh S, Oseroff AR. Laser and photodynamic therapy in the management of cutaneous malignancies. Clin Dermatol 2001; 19:328-339.
26. Nathanson L, Schoenfeld D, Regelson W, Colsky J, Mittelman A. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. Cancer 1979; 43:1630-1635.
27. Krown SE, Hilal EY, Pinsky CM, Hirshaut Y, Wanebo HJ, Hansen JA, et al. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer 1978; 42:2648-2660.
28. Mastrangelo MJ, Sulit HL, Prehn L, Bornstein RS, Yarbro JW, Prehn RT. Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 1976; 37:684-692.
29. Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 1978; 41:2456-2463.
30. Wenig BL, Werner JA, Castro DJ, Sridhar KS, Garewal HS, Kehrl W, et al. The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002; 128 (8):880-885.
31. Common Toxicity Criteria, Version 2.0, Cancer Therapy Evaluation Program, DCTD, NCI, NIH, DHHS, National Cancer Institute, April 1999.
32. SAS Institute Inc. SAS/STAT® Changes and Enhancements through Release 6.12. Cary, North Carolina: SAS Institute Inc.; 1997.
33. Lattanzi SC, Tosteson T, Chertoff J, Maurer LH, O'Donnell J, LeMarbre PJ, et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995; 5:365-369.
34. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
35. Keilholz U, Goey SH, Punt CJA, Proebstle TM, Salzmann R, Scheibenbogen C, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15:2579-2588.
36. Burris HA III, Vogel CL, Castro D, Mishra L, Schwarz M, Spencer S, et al. Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study. Otolaryngol Head Neck Surg 1998; 118:496-503.
37. Fernando I, Eisenberg PD, Roshon S, Mansi J, Mills G, de Vries E. Intratumoral focused chemotherapy with cisplatin/epinephrine injectable gel for palliative treatment of metastatic breast cancer. Eur J Cancer 1999; 35 (suppl 4):S318.
38. Harbord M, Dawes RFH, Barr H, Giovannini M, Viens P, Eysselein V, Mishra L, Orenberg EK, Bown SG. Palliation of patients with dysphagia due to advanced esophageal cancer by endoscopic injection of cisplatin/epinephrine gel. Gastrointest Endosc 2002; 56:644-651.
39. Monga SPS, Wadleigh R, Adib H, Harmon JW, Berlin M, Mishra L. Endoscopic treatment of gastric cancer with intratumoral cisplatin/epinephrine injectable gel: a case report. Gastrointest Endosc 1998; 48:415-417.
40. Benson A III, Johnson PJ, Leung TWT, Vogl TJ, Gores G, Giovannini M, et al. Percutaneous cisplatin/epinephrine (CDDP/epi) injectable gel tumor ablation in patients with unresectable primary and secondary hepatic cancers. Hepatology 2000; 32:231a.
41. Johnson P, Leung TWT, Vogl TJ, Gores G, Giovannini M, O'Grady J, et al. Management of unresectable hepatocellular carcinoma (HCC) with cisplatin/epinephrine (CDDP/epi) injectable gel administered percutaneously: radiologic and histologic evidence of tumor ablation. Ann Oncol 2000; 11 (suppl 4):139.
42. Vogl TJ, Engelmann K, Mack MG, Straub R, Eichler K, Hochmuth K, Orenberg E. CT-guided intratumoral administration of cisplatin/epinephrine gel for the treatment of malignant liver tumors. Brit J Cancer 2002; 86:524-529.
43. Kitchell BE, Brown DM, Luck EE, Woods LL, Orenberg EK, Bloch DA. Intralesional implant for treatment of primary oral malignant melanoma in dogs. JAVMA 1994; 204:229-236.
44. Yu NY, Patawaran MB, Chen JY, Orenberg EK, Brown DM, Luck EE. Influence of treatment sequence on efficacy of fluorouracil and cisplatin intratumoral drug delivery in vivo. Can J Sci Am 1995; 1:215-221.
45. Atkins MB. Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am 1998; 12:877-902.
46. Hellman S. Principles of cancer management: radiation therapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 6th edition. Philadelphia: Lippincott Williams & Wilkins; 2001, pp. 283-284.
47. Mok TSK, Kanekal S, Lin XR, Leung TWT, Chan ATC, Yeo W, et al. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. Cancer 2001; 91:2369-2377.
48. Malhotra H, Plosker GL. Cisplatin/epinephrine injectable gel. Drugs Aging 2001; 18:787-793.